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Abstract
Background: Fractionated plasma metanephrine measurements are commonly used in
biochemical testing in search of pheochromocytoma.
Methods: We aimed to critically appraise the diagnostic efficacy of fractionated plasma free
metanephrine measurements in detecting pheochromocytoma. Nine electronic databases, meeting
abstracts, and the Science Citation Index were searched and supplemented with previously
unpublished data. Methodologic and reporting quality was independently assessed by two
endocrinologists using a checklist developed by the Standards for Reporting of Diagnostic Studies
Accuracy Group and data were independently abstracted.
Results: Limitations in methodologic quality were noted in all studies. In all subjects (including
those with genetic predisposition): the sensitivities for detection of pheochromocytoma were
96%–100% (95% CI ranged from 82% to 100%), whereas the specificities were 85%–100% (95% CI
ranged from 78% to 100%). Statistical heterogeneity was noted upon pooling positive likelihood
ratios when those with predisposition to disease were included (p < 0.001). However, upon
pooling the positive or negative likelihood ratios for patients with sporadic pheochromocytoma (n
= 191) or those at risk for sporadic pheochromocytoma (n = 718), no statistical heterogeneity was
noted (p = 0.4). For sporadic subjects, the pooled positive likelihood ratio was 5.77 (95% CI = 4.90,
6.81) and the pooled negative likelihood ratio was 0.02 (95% CI = 0.01, 0.07).
Conclusion: Negative plasma fractionated free metanephrine measurements are effective in ruling
out pheochromocytoma. However, a positive test result only moderately increases suspicion of
disease, particularly when screening for sporadic pheochromocytoma.
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Pheochromocytoma is a rare tumor of chromaffin cells in
the adrenal medulla or sympathetic ganglia, which can
present clinically as hypertension, spells (of hypertension,
palpitations, headache, or other symptoms), or an inci-
dentally discovered adrenal mass seen on imaging studies
[1-5]. The annual incidence is only 1.55 to 8 cases per mil-
lion [6-10], although rare genetic mutations can increase
predisposition [11,12]. As many common clinical syn-
dromes (such as refractory hypertension) can mimic
symptoms and signs of pheochromocytoma, the condi-
tion is "frequently sought and rarely found" [2,13,14].
The biochemical screening test used for diagnosing pheo-
chromocytoma is institution and laboratory-dependent
with variable performance, and an "ideal" test for pheo-
chromocytoma has been sought over the years as false or
uninterpretable results are not uncommon with some tra-
ditional tests [1,14-47]. Recently, measurement of frac-
tionated plasma free metanephrines by high performance
liquid chromatography and electrochemical detection has
been endorsed by investigators at the National Institute of
Health (NIH) as the single best test for biochemical
screening for pheochromocytoma [48-61]. The objective
of the current study is to systematically review the litera-
ture to determine the diagnostic efficacy of measurements




We included studies of adults who underwent measure-
ment of fractionated plasma free metanephrines for the
purpose of diagnostic testing. All studies had a "methods"
section and included at least 10 subjects with pheochro-
mocytoma (or paraganglioma) and at least 10 subjects
without the diagnosis. Studies in which more than a third
of subjects were below the age of 18 years or focussing on
patients with end stage renal disease were excluded. In the
case of multiple concurrent publications from the same
research group, only the article describing the largest
number of subjects tested were included. Updated unpub-
lished data obtained from authors was included. The term
pheochromocytoma refers to adrenal pheochromocyto-
mas and extra-adrenal paragangliomas. The method of
Lenders was used for measurement of fractionated plasma
metanephrines [49]. Plasma metanephrine measure-
ments in the setting of clonidine-suppression or glucacon-
stimulation were excluded.
Data sources
The following electronic databases were searched with no
language restrictions: Medline (1989–February 2003),
Pre-Medline February 21, 2003, Cochrane Database for
Systematic Reviews, American College of Physicians Jour-
nal Club (September 1991–October 2002), Database of
Abstracts of Reviews, the Controlled Clinical Trials Data-
base, CANCERLIT (1975–2002), Healthstar 1975–
December 2002, and CINAHL 1982 to week 1 February,
2003. The search strategy used incorporated the MESH
heading "metanephrine" or the textword roots of
"metanephrine" or "normetanephrine", as well as the tex-
tword "plasma", and the MESH headings of "paragangli-
oma", "pheochromocytoma," or textword roots of
"paraganglioma", "pheochromocytoma", or "phaeochro-
moctyoma", and the MESH headings "sensitivity and spe-
cificity", or "diagnosis", or the textword roots of
"sensitiv", "specific", or "diagnos", or the textword "likeli-
hood ratio". We also searched the Web of Science for arti-
cles citing the methodologic study of Lenders [49] and
hand-searched the abstract books of the 82nd to 84th
annual meetings of the Endocrine Society (2000–2002).
Two endocrinologists independently screened the titles
and abstracts obtained through the electronic search and
all full-text articles, deemed potentially relevant by either
of the reviewers, were obtained for formal review. After
reviewing the full-text articles, both reviewers agreed on
which articles would be included in the systematic review.
Assessment of methodologic quality and quality of 
reporting of included studies and data abstraction
Each of the two reviewers independently assessed the
quality of methodology and reporting of the included
studies, using a 25-item checklist developed by the Stand-
ards for Reporting of Diagnostic Studies Accuracy Group
(STARD) [62] (Table 1). The two reviewers also independ-
ently abstracted the data from published studies in dupli-
cate and consensus was reached on the final data
presented. In the case of updated unpublished data from
the Mayo Clinic, Rochester, ethics board approval and
signed consent was obtained for chart review.
Statistical analyses
A kappa statistic was calculated to measure agreement
between the two reviewers in assessment of methodologic
and reporting quality [63]. For sensitivities, specificities,
and likelihood ratios, 95% confidence intervals were cal-
culated using Wilson's method [64]. The Score Method
was used for calculation of 95% CI of likelihood ratios
when a zero cell was noted [64]. Likelihood ratios (LRs)
predicting the presence of pheochromocytoma given a
positive test result (sensitivity/1-specificty) and a negative
test result (1-sensitivity/specificity) were calculated for
each included study. Of note, a positive LR above 10 and
negative LR below 0.1 has been noted to generate large
changes from pre-test to post-test probability of disease,
often resulting in a large change in patient management;
whereas positive LRs between 5 and 10 and negative LRs
between 0.1 and 0.2 are considered to generate moderate
shifts in pre-test to post-test probability of disease [65-68].Page 2 of 11
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tory used the assay technique of Lenders [49] with an
upper limit of a population-based 95% reference range
used as the basis for positivity of the test. Either a free
metanephrine or free normetanephrine fraction value had
to be above the reference range cut-off, for a test to be con-
sidered positive [69]. A chi-squared test of homogeneity
(Q-statistic) was performed for pooled studies [70,71]. A
random effects model was used for pooling of likelihood
ratios using Review Manager 4.1 [66,70,72]. A funnel plot
was constructed to visually assess for publication bias of
pooled studies [73,73]. A separate analysis was performed
for all pheochromocytomas and for sporadic pheochro-
mocytomas (those without known genetic predisposition
to the disease).
Results
Studies included in the systematic review
We retrieved 101 unique references; however, 41 of the
references were excluded as they were published prior to
the specific technique of Lenders being described in 1993
[49], leaving 60 references for consideration of inclusion
in the systematic review [1,4,16-18,22,24,26,44,49-
61,74-111]. Of these 60 articles, 36 were deemed
potentially relevant by either endocrinologist/reviewer
[1,4,16-18,22,24,49-59,61,76,78,82-85,88,89,97-
104,104,111]. Thereafter, 13 studies were excluded
because of overlap of patients from the same institution or
group of institutions in another publication [49,50,52-
57,61,82,84,85,111]. Of the 23, full-text studies reviewed,
18 were excluded as they lacked new data on sensitivity
and specificity of fractionated plasma metanephrine
measurements in at least 10 patients with and 10 patients
without pheochromocytoma or lacked a methods section
[1,4,16-18,22,24,51,58,59,61,76,78,82-
85,88,89,97,98,100-104], or did not cite the Lenders
method [99,100].
The remaining studies included in the systematic review
were authored by: Lenders et al. [51], Raber et al. [59], and
Table 1: STARD checklist for the reporting of studies of diagnostic accuracy (shortened item description)
Selection and topic Item Mayo NIH Vienna
R1* R2* R1* R2* R1* R2*
TITLE/ABSTRACT 1. Identify study of diagnostic accuracy • • • • • •
INTRODUCTION 2. State the research question • • • • • •
METHODS
Participants 3. Describe study population • • • • • •
4. Describe participant recruitment • • • •
5. Describe participant sampling • • •
6. Describe if prospective or retrospective • • • • •
Test Methods 7. Reference standard and rationale • • • • • •
8. Technical specifications described or referenced • • • • • •
9. Description of rationale for cut-offs for index tests and reference standards • • • • •
10. Description of the number and training of persons executing the tests
11. Description of blinding of test readers
Statistical Methods 12. Description of calculations of diagnostic accuracy and uncertainty • • • • • •
13. Description of calculations of test reproducibility •
RESULTS
Participants 14. Description of duration of study • • • •
15. Description of clinical and demographic description of participants • • • • • •
16. Description of the number of participants satisfying inclusion criteria that did 
not undergo the index test or reference standard, and why
• •
Test Results 17. Description of the time interval from the index test to the reference standard 
and any treatment administered between
18. Description of the severity of disease in those with the target condition; other 
diagnoses in participants without the target condition
• • •
19. A cross-tabulation of the results of the index tests (including indeterminate and 
missing tests)
• • • • • •
20. Any adverse events from performing the index or reference tests
Estimates 21. Estimates of diagnostic accuracy with statistical uncertainty • • •
22. Description of how indeterminate results were handled • •
23. Estimates of variability between subgroups of patients, readers, or centres • • • •
24. Estimates of test reproducibility •
DISCUSSION 25. Discussion of the clinical applicability of the findings • • • • • •
*R1 and R2, refer to Reviewer 1 and 2, •indicates criteria fulfilled (at least in part)Page 3 of 11
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NIH, Vienna, and Mayo papers or studies, respectively.
Summary of methodologic and reporting quality of 
included studies
The methodologic and reporting quality of the three
included studies was evaluated independently by two
endocrinologists using a 25-item checklist developed by
the STARD steering committee (Table 1) [112]. The kappa
statistic for measuring agreement between the two review-
ers in assessing the STARD items addressed in each study
was 0.82 for the Mayo study, 0.65 for the NIH study, 0.60
for the Vienna study.
Specific threats to internal validity of the studies were
appraised. In all of the studies, subjects who had signs,
symptoms, or imaging characteristics that warranted test-
ing were included (as opposed to asymptomatic controls).
However, blinded adjudication of test interpretation and
diagnoses was not performed in any of the studies. In
terms of limitation of selection bias, consecutive patient
recruitment was noted only in the Mayo study [18]. Data
was collected prospectively in the NIH study, retrospec-
tively in the Mayo study, and method of data collection
was unclear in Vienna study [18,51,59].
In terms of limiting verification bias, only the NIH inves-
tigators stated that the results of plasma metanephrine
measurements were not used in guiding further evalua-
tion. In the Mayo and Vienna studies, all pheochromocy-
toma patients had histologic confirmation, whereas in the
NIH study, either histologic confirmation or evidence of
inoperable metastatic pheochromocytoma on imaging
was deemed adequate for diagnosis. In subjects without
pheochromocytoma, different criteria were used to define
a negative diagnosis in all three studies: alternative diag-
nosis after subspecialty evaluation in the Mayo study,
alternative adrenal histology in the Vienna study, and, in
the NIH study, either lack of radiological evidence of a
tumor on imaging or pathologic examination of a non-
pheochromocytoma adrenal mass, or patient follow-up of
2 years or more. Thus, only in the Vienna study [59], was
a histologic gold standard applied to all patients, regard-
less of disease status.
Overall, the least number of STARD methodologic and
reporting criteria were addressed in the case-control
design Vienna study [59]. The Vienna study was also the
smallest, comparing 17 patients with pheochromocytoma
to 14 subjects without pheochromocytoma, and showed
the highest diagnostic accuracy (sensitivity and specificity
each 100 percent). Of note, the dichotomous nature of
case-control designs may overestimate the accuracy of
diagnostic tests [113].
Diagnostic efficacy of measurements of fractionated 
plasma metanephrines in diagnosis of pheochromocytoma
The cut-off values for positivity as well as the conditions
of measurement of fractionated plasma metanephrines
were slightly different in the Mayo study compared to the
NIH and Vienna studies. In the NIH study, the criterion
for test positivity was a metanephrine fraction of 0.3
nmol/L and/or a normetanephrine fraction of 0.6 nmol/
L, based on a laboratory reference range [51]; and the
same criterion was used in the Vienna study [59]. In the
Mayo study, the criterion for positivity was a metane-
phrine fraction of 0.5 nmol/L or a normetanephrine frac-
tion of 0.9 nmol/L, based on a 95% reference range of
Mayo Medical Laboratories [18]. Acetaminophen was
generally avoided prior to measurements of plasma free
metanephrines in all studies. Furthermore, subjects were
supine for at least 20 minutes with an indwelling intrave-
nous cannula in both the NIH and Vienna studies, but not
the Mayo study.
Demographics of patients in the included studies were
examined (Table 2). A description of patients in the
updated (published and unpublished) database from
Mayo Clinic Rochester from January 1, 1999 to November
29, 2001 is herein provided. The updated database
included the 349 subjects (including 33 patients with
pheochromocytoma) that were tested between January 1,
1999 and November 27, 2000 [18], as well as another 158
subjects (including 23 with pheochromocytoma) that
were recruited between November 28, 2000 and Novem-
ber 9, 2001. The newly added 158 subjects were consecu-
tive patients seen at the Mayo Clinic Rochester, who did
not have a known familial predisposition to pheochro-
mocytoma, were not tested during the first series, and had
complete measurements for fractionated plasma metane-
phrines as well as 24-hour urinary total metanephrines
and catecholamines. In both series, patients without phe-
ochromocytoma were screened in clinical practice
because of one or more of the following reasons:
hypertension, spells (such as episodes of anxiety, sweat-
ing, palpitations, or headache), adrenal abnormality on
imaging, previous history of surgically resected pheochro-
mocytoma, or known familial predisposition to pheo-
chromocytoma. Upon combining the published and
unpublished data, there were a total of 56 patients with
pheochromocytoma (39 of whom were truly sporadic
with no known genetic predisposition to pheochromocy-
toma and no previous history of pheochromocytoma,
70%) and 445 subjects without pheochromocytoma (399
with no known genetic predisposition to pheochromocy-
toma, 90% percent) (Table 2).
The main difference in demographic characteristics
between the included studies was that the majority of sub-
jects without pheochromocytoma in the NIH study had aPage 4 of 11
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in the Vienna and Mayo studies did not (Table 2). Further-
more, the non-pheochromocytoma subjects in the Mayo
study appeared older with a mean age above 50 years
(Table 2). Also, in the Vienna study, all subjects without
pheochromocytoma had a known abnormality of the
adrenal, whereas this was not the case in all patients in the
NIH and Mayo studies.
The diagnostic efficacy of measurements of fractionated
plasma metanephrines in detection of pheochromocy-
toma from the three included studies (including updated
unpublished data in the Mayo study) are shown in Table
3[18,51,59]. For all patients, the sensitivities ranged from
96% to 100%, and 95% CI ranged from 82% to 100%,
whereas the specificities ranged from 85% to 100% with
95% CI ranging from 78% to 100%. For subjects either at
risk for or with sporadic pheochromocytoma, the sensitiv-
ities ranged from 97% to 100% (95% CI ranged from 79%
to 100%), whereas the specificities ranged from 82% to
100% (95% CI ranged from 79% to 100%) (Table 3). Fur-
thermore, for all patients, the positive likelihood ratios
ranged from 6.31 to 29.17 and the negative LRs ranged
from 0.02 to 0.03 (Table 3). The positive LRs for all
patients with or at risk for sporadic pheochromocytoma
(with cured patients who have had a previous diagnosis of
pheochromocytoma excluded from the Mayo study)
ranged from 6.07 to 29.00 and the negative LRs ranged
from 0.031 to 0.03 (Table 3).
Upon pooling of the positive likelihood ratios for all
patients (n = 287 with pheochromocytoma, n = 1103
without pheochromocytoma), significant heterogeneity
was indicated using chi-squared test (X2 = 8.20, degrees of
freedom = 2, p = 0.017), indicating that studies may have
been different secondary to differences in populations
studied, assay technique, or reference standard (Figure 1).
Although pooling of statistically heterogenous data is of
questionable value and should be considered exploratory,
the pooled positive likelihood ratio was noted to be 7.86
(95% CI= 5.17, 11.94), which was significantly higher
than 1 (z = 9.66, p < 0.001). The pooled estimate of neg-
ative likelihood ratios for all patients was 0.02 (95% CI=
0.01, 0.04, z = -8.60, p < 0.001 for the value being less
than 1), with no evidence of statistical heterogeneity (X2 =
0.20, p = 0.91) (Figure 2). The funnel plots examining for
publication bias were not interpretable as they were lim-
ited by very few studies included in the analyses.
Next, we determined the diagnostic efficacy of fraction-
ated plasma metanephrine measurements in patients at
risk for sporadic disease. We included 191
pheochromocytoma patients and 718 non-genetically
predisposed non-pheochromocytoma patients and found
the pooled estimate of a positive likelihood ratio was 5.77
(95% CI = 4.90, 6.81, z = 20.85, p < 0.001 for the differ-
ence being greater than 1 (with no statistically significant
evidence of heterogeneity between studies, X2 = 1.84, p =
0.4) (Figure 3). The pooled estimate of negative likeli-
hood ratios for sporadic subjects was 0.02 (95% CI= 0.01,
0.07, z = -6.31, p < 0.001 for the value being less than 1)
(no evidence of statistical heterogeneity, X2 = 1.08, p =
0.58) (Figure 4).
Discussion
Upon systematically reviewing the literature, we have
determined that fractionated plasma metanehrine meas-
urements are highly sensitive in detecting pheochromocy-
toma, although specificity of these measurements may be
variable, particularly in testing for sporadic disease. A neg-
ative fractionated plasma metanephrine measurement is
highly effective in ruling out disease. However, a positive
test result only moderately increases suspicion of disease,
particularly in low risk subjects being tested for sporadic
pheochromocytoma.
Table 2: Demographic characteristics of subjects in included studies
Demographic characteristic Mayo Clinic* NIH Vienna
Years of recruitment of patients 1999–2001 1994–2001 Unclear
Proportion of female gender of all patients 287/507 (57%) 475/858 (55%) 24/31 (77%)
Proportion of sporadic pheochromocytoma patients (%) 39/56 (70%) 138/214 (64%) 14/17 (82%)
Proportion of non-pheochromocytoma patients with no genetic predisposition to 
disease†
399/445 (90%) 305/644 (47%) Unclear
Mean age, years (range) of all pheochromocytoma patients 49 (16–83) 33,47‡ (8–78) 46
Mean age, years (range) of all non-pheochromocytoma patients 52 (7–86) 38,47‡ (8–77) 44
*Published Mayo Clinic data was supplemented with new data. † Subjects with sporadic pheochromocytoma and those at risk for sporadic 
pheochromocytoma had no known genetic predisposition to the disease and no previous history of pheochromocytoma. 6 subjects without 
pheochromocytoma who had "interfering substances" noted upon measurement of the metanephrine fraction were excluded. ‡ Mean age of 
pheochromocytoma patients in NIH study: 33 years for genetically predisposed patients and 47 for sporadic patients. Mean age of 
nonpheochromocytoma patients in NIH study: 38 for genetically predisposed patients, 47 for sporadic patients.Page 5 of 11
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an individual patient's probability of sporadic pheochro-
mocytoma, given a positive biochemical test result. The
pre-test probability of sporadic pheochromocytoma
(prevalence) is estimated to be 0.5% among screened
hypertensive patients [114], and 5.1% among incidentally
discovered adrenal masses >1 cm in diameter in absence
of symptoms of adrenal disease [adrenal "incidentalo-
mas"] [3]. For a patient with positive fractionated plasma
metanephrines, the post-test probability of sporadic phe-
ochromocytoma would be 2.8% in the patient with
hypertension, and 23.7% in the patient with an adrenal
incidentaloma. In other words 97.2% of hypertensive
subjects and 76.3% of subjects with incidentaloma would
not be expected to have a pheochromocytoma, in spite of
a positive test result. Similarly, we may estimate the prob-
ability of sporadic pheochromocytoma, given negative
fractionated plasma metanephrine measurements, using
the pooled negative likelihood ratio value of 0.02. For a
patient with normal fractionated plasma metanephrine
measurements, the post-test probability of sporadic
pheochromocytoma would be estimated to be 0.01% in
the patient with hypertension and 0.11% in the patient
with an adrenal incidentaloma.
Table 3: Sensitivity and specificity of measurements of fractionated plasma metanephrines
Sensitivity (95% CI)* Specificity (95% CI)* Likelihood ratio of a 
positive test* (95% CI)*
Likelihood ratio of a 
negative test* (95% CI)*
ALL PATIENTS
Mayo Clinic† 96% (54/56) (88%, 99%) 85% (377/445) (81%, 88%) 6.31 (5.04, 7.90) 0.02 (0.00, 0.15)
NIH 99% (211/214) (96%, 100%) 89% (575/644) (87%, 91%) 9.20 (7.36, 11.51) 0.02 (0.01, 0.05)
Vienna 100% (17/17) (82%, 100%) 100% (14/14) (78%, 100%) 29.17 (1.91, 445.60) 0.03 (0.00, 0.44)
SPORADIC PATIENTS
Mayo Clinic 97% (38/39) (87%, 100%) 84% (335/399) (80%, 87%) 6.07 (4.83, 7.65) 0.03 (0.00, 0.21)
NIH 99% (137/138) (99%, 100%) 82% (249/305) (77%, 86%) 5.41 (4.27, 6.85) 0.01 (0.00, 0.06)
Vienna 100% (14/14) (79%, 100%) 100% (14/14) (79%, 100%) 29.00 (1.90, 443.27) 0.03 (0.00, 0.53)
*Calculated † 6 subjects without pheochromocytoma who had "interfering substances" noted upon measurement of the metanephrine fraction 
were excluded.
Likelihood ratios (LRs) of a positive fractionated plasma metanephrine measurement predicting pheochromocytoma in all patients (including sporadic and genetically-pr ispo ed patients)Figure 1
Likelihood ratios (LRs) of a positive fractionated plasma metanephrine measurement predicting pheochromocytoma in all 
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included studies may have been subject to multiple meth-
odologic limitations, possibly resulting in over-estima-
tion of the diagnostic efficacy of fractionated plasma
metanephrine measurements. Also, many of the patients
studied had known genetic predisposition, previously sur-
gically cured disease, or metastatic pheochromocytoma,
thereby limiting the external generalizability of our sum-
mary. Furthermore, positivity cut-offs were derived some-
what differently between the studies, possibly accounting
for the observed heterogeneity of positive likelihood
ratios between studies. The criterion for positivity in the
NIH and Vienna studies were based on a NIH laboratory
reference range [51,59]; whereas a higher criterion was
used in the Mayo study, based on a 95% reference range
derived by Mayo Medical Laboratories [18]. The Mayo ref-
Likelihood ratios (LRs) of a negative fractionated plasma metanephrine measurement predicting pheochromocytoma in all patients (including sporadic and genetically-predis o ed patients)Figure 2
Likelihood ratios (LRs) of a negative fractionated plasma metanephrine measurement predicting pheochromocytoma in all 
patients (including sporadic and genetically-predisposed patients)
Likelihood ratios (LRs) of a positive fractionated plasma metanephrine measurement predicting pheochromocytoma in patients with sporadic pheochromocytoma o  a  risk for sporadic pheoc romocytomaFigure 3
Likelihood ratios (LRs) of a positive fractionated plasma metanephrine measurement predicting pheochromocytoma in patients 
with sporadic pheochromocytoma or at risk for sporadic pheochromocytomaPage 7 of 11
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were not subject to indwelling intravenous cannulation or
prolonged supine rest, possibly accounting for the slightly
higher cut-offs. Indeed, a laboratory medicine tradition
has to derive normal ranges from "normal" healthy indi-
viduals as such individuals reflect the general population
and are easily accessible for study. Such ranges are reflec-
tive of "non-disease", but their use may be subject to
excessively high rates of false positive tests in subjects with
conditions mimicking a disease in question who are likely
to be tested clinically (such as patients with refractory
hypertension in the case of pheochromocytoma testing).
Limitations of deriving "non-disease" ranges in subjects
with conditions mimicking a disease in question (such as
hypertensive patients in this case) may include decreasing
sensitivity of testing and the potential for missing a poten-
tially fatal, treatable diagnosis.
It is notable that data on the efficacy of fractionated
plasma metanephrine measurements in detection of phe-
ochromocytoma is limited to only three laboratories with
patients recruited from 6 clinical centres. This may be a
reflection of the labor-intensive, time-consuming nature
of the high performance liquid chromatography and elec-
trochemical detection method as well as the nuisance of
potential interference with acetaminophen [115]. A newer
method described by Roden et al. may circumvent the
acetaminophen interference issue, but is also quite labor-
intensive and might not be suitable for widespread clini-
cal laboratory use [104]. A method of measurement of
fractionated plasma metanephrines using liquid chroma-
tography with tandem mass spectrometry shows promise
in terms of improved specificity and rapidity of processing
of multiple samples [115]. Further clinical study is indi-
cated to validate such newer assays in clinical patient
populations.
Conclusions
Where does this evidence summary leave the physician
who is faced with the common clinical scenario of a
patient with refractory hypertension or incidentally found
adrenal mass? Firstly, the clinician must assess the relative
likelihood of pheochromocytoma in each clinical case
and decide whether testing is warranted. Decisions for the
type of test performed may be subject to clinical availabil-
ity, cost, and clinical experience of the ordering physician
and local laboratory. If measurement of fractionated
plasma metanephrines is performed, a positive test result
in a high risk setting (such as a genetically predisposed
individual or an individual with a known adrenal mass
characteristic of pheochromocytoma) or a negative result
in a low risk setting (such as a patient with refractory
hypertension) is highly predictive of confirming or refut-
ing the diagnosis, respectively. However, a negative result
in a high risk setting (such as testing of a genetically pre-
disposed patient or a patient with a known vascular
adrenal mass), or a positive result in a low risk setting




Likelihood ratios (LRs) of a negative fractionated plasma metanephrine measurement predicting pheochromocytoma in patients with sporadic pheochromocytoma or at risk for sporadic pheochromocytomaFigure 4
Likelihood ratios (LRs) of a negative fractionated plasma metanephrine measurement predicting pheochromocytoma in 
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